LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (“ScienTech”) disclosed a series of on-market share repurchases conducted between 26 June and 16 July 2026, acquiring an aggregate 1.90 million H-shares for future cancellation at a volume-weighted average price of HK$10.33 per share. Total consideration reached approximately HK$19.63 million.

Across 12 trading sessions, daily repurchase volumes ranged from 5,000 to 528,000 shares, with prices spanning HK$9.87 to HK$10.88. The most recent transaction on 16 July involved 38,000 shares at between HK$10.70 and HK$10.88, costing HK$0.41 million.

Key capital metrics remain unchanged for now: • Issued share capital: 346.75 million H-shares as at both 15 July and 16 July 2026. • Treasury shares: Nil; all repurchased shares await formal cancellation. • Post-cancellation impact: Outstanding shares will fall by 0.55% to roughly 344.85 million, once the 1.90 million repurchased shares are cancelled.

Repurchase mandate status: • Authorised capacity (approved 22 May 2026): up to 34.67 million shares. • Utilisation to date: 1.90 million shares, representing 5.48% of the mandate and 0.55% of issued share capital at mandate date. • Remaining headroom: about 32.78 million shares.

Regulatory timetable: • Under Hong Kong Listing Rule 10.06(3)(a), ScienTech is subject to a moratorium on issuing, selling or transferring shares for 30 days following the latest repurchase, ending 15 August 2026.

All buybacks were executed on the Hong Kong Stock Exchange in compliance with the company’s board authorisation and relevant listing regulations.